Differences in β-adrenergic receptor density and adenylate cyclase activity between normal and leukaemic leukocytes

Elisabeth M. Paietta, J. D. Schwarzmeier

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

An identical class of high-affinity binding sites for the 125I-labelled β-adrenergic antagonist hydroxybenzylpindolol, was identified on intact human normal and leukaemic peripheral blood leukocytes. On normal unfractionated lymphocytes, polymorphonuclear leukocytes, and monocytes, receptor density did not differ significantly (1200-1400 receptors per cell; P > 0.3), but it was higher on B- than on T-lymphocytes (P < 0.05). In leukaemia, monocytic blast cells expressed highest receptor numbers, whereas very low receptor density was seen on the pathologic B-cells from chronic lymphocytic leukaemia. Among normal leukocytes, adenylate cyclase activation by hormones (isoproterenol, prostaglandin E1, histamine) and sodium fluoride was strongest in plasma membranes from monocytes, but very weak in polymorphonuclear leukocytes either due to uncoupling of hormone receptors from adenylate cyclase or to low catalytic activity. In T-cells, enzyme activity was significantly lower than in B-cells. Loss of adenylate cyclase sensitivity to hormones and fluoride occurred in leukaemic cells from chronic and acute lymphocytic leukaemia.

Original languageEnglish (US)
Pages (from-to)339-346
Number of pages8
JournalEuropean Journal of Clinical Investigation
Volume13
Issue number4
StatePublished - 1983
Externally publishedYes

Fingerprint

Adenylyl Cyclases
Adrenergic Receptors
Leukocytes
T-cells
Hormones
B-Cell Chronic Lymphocytic Leukemia
Monocytes
Neutrophils
Cells
T-Lymphocytes
Sodium Fluoride
Adrenergic Antagonists
Lymphocytes
Alprostadil
Enzyme activity
Cell membranes
Fluorides
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isoproterenol
Histamine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{040e2541f81640d59ccdc803a7cfdf8d,
title = "Differences in β-adrenergic receptor density and adenylate cyclase activity between normal and leukaemic leukocytes",
abstract = "An identical class of high-affinity binding sites for the 125I-labelled β-adrenergic antagonist hydroxybenzylpindolol, was identified on intact human normal and leukaemic peripheral blood leukocytes. On normal unfractionated lymphocytes, polymorphonuclear leukocytes, and monocytes, receptor density did not differ significantly (1200-1400 receptors per cell; P > 0.3), but it was higher on B- than on T-lymphocytes (P < 0.05). In leukaemia, monocytic blast cells expressed highest receptor numbers, whereas very low receptor density was seen on the pathologic B-cells from chronic lymphocytic leukaemia. Among normal leukocytes, adenylate cyclase activation by hormones (isoproterenol, prostaglandin E1, histamine) and sodium fluoride was strongest in plasma membranes from monocytes, but very weak in polymorphonuclear leukocytes either due to uncoupling of hormone receptors from adenylate cyclase or to low catalytic activity. In T-cells, enzyme activity was significantly lower than in B-cells. Loss of adenylate cyclase sensitivity to hormones and fluoride occurred in leukaemic cells from chronic and acute lymphocytic leukaemia.",
author = "Paietta, {Elisabeth M.} and Schwarzmeier, {J. D.}",
year = "1983",
language = "English (US)",
volume = "13",
pages = "339--346",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Differences in β-adrenergic receptor density and adenylate cyclase activity between normal and leukaemic leukocytes

AU - Paietta, Elisabeth M.

AU - Schwarzmeier, J. D.

PY - 1983

Y1 - 1983

N2 - An identical class of high-affinity binding sites for the 125I-labelled β-adrenergic antagonist hydroxybenzylpindolol, was identified on intact human normal and leukaemic peripheral blood leukocytes. On normal unfractionated lymphocytes, polymorphonuclear leukocytes, and monocytes, receptor density did not differ significantly (1200-1400 receptors per cell; P > 0.3), but it was higher on B- than on T-lymphocytes (P < 0.05). In leukaemia, monocytic blast cells expressed highest receptor numbers, whereas very low receptor density was seen on the pathologic B-cells from chronic lymphocytic leukaemia. Among normal leukocytes, adenylate cyclase activation by hormones (isoproterenol, prostaglandin E1, histamine) and sodium fluoride was strongest in plasma membranes from monocytes, but very weak in polymorphonuclear leukocytes either due to uncoupling of hormone receptors from adenylate cyclase or to low catalytic activity. In T-cells, enzyme activity was significantly lower than in B-cells. Loss of adenylate cyclase sensitivity to hormones and fluoride occurred in leukaemic cells from chronic and acute lymphocytic leukaemia.

AB - An identical class of high-affinity binding sites for the 125I-labelled β-adrenergic antagonist hydroxybenzylpindolol, was identified on intact human normal and leukaemic peripheral blood leukocytes. On normal unfractionated lymphocytes, polymorphonuclear leukocytes, and monocytes, receptor density did not differ significantly (1200-1400 receptors per cell; P > 0.3), but it was higher on B- than on T-lymphocytes (P < 0.05). In leukaemia, monocytic blast cells expressed highest receptor numbers, whereas very low receptor density was seen on the pathologic B-cells from chronic lymphocytic leukaemia. Among normal leukocytes, adenylate cyclase activation by hormones (isoproterenol, prostaglandin E1, histamine) and sodium fluoride was strongest in plasma membranes from monocytes, but very weak in polymorphonuclear leukocytes either due to uncoupling of hormone receptors from adenylate cyclase or to low catalytic activity. In T-cells, enzyme activity was significantly lower than in B-cells. Loss of adenylate cyclase sensitivity to hormones and fluoride occurred in leukaemic cells from chronic and acute lymphocytic leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=0020629672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020629672&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 339

EP - 346

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 4

ER -